FibroGen (FGEN) Competitors $7.15 -0.20 (-2.72%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$7.30 +0.15 (+2.10%) As of 07/11/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. CHRS, MGNX, ZNTL, ELUT, TCRX, EXOZ, CLYM, CYCC, IVVD, and FBRXShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Coherus Oncology (CHRS), MacroGenics (MGNX), Zentalis Pharmaceuticals (ZNTL), Elutia (ELUT), TScan Therapeutics (TCRX), eXoZymes (EXOZ), Climb Bio (CLYM), Cyclacel Pharmaceuticals (CYCC), Invivyd (IVVD), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Coherus Oncology MacroGenics Zentalis Pharmaceuticals Elutia TScan Therapeutics eXoZymes Climb Bio Cyclacel Pharmaceuticals Invivyd Forte Biosciences FibroGen (NASDAQ:FGEN) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk. Which has more risk & volatility, FGEN or CHRS? FibroGen has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Do insiders and institutionals have more ownership in FGEN or CHRS? 72.7% of FibroGen shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 2.0% of FibroGen shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor FGEN or CHRS? In the previous week, Coherus Oncology had 1 more articles in the media than FibroGen. MarketBeat recorded 2 mentions for Coherus Oncology and 1 mentions for FibroGen. FibroGen's average media sentiment score of 1.89 beat Coherus Oncology's score of 0.94 indicating that FibroGen is being referred to more favorably in the media. Company Overall Sentiment FibroGen Very Positive Coherus Oncology Positive Do analysts rate FGEN or CHRS? FibroGen currently has a consensus target price of $250.00, suggesting a potential upside of 3,396.50%. Coherus Oncology has a consensus target price of $4.68, suggesting a potential upside of 432.20%. Given FibroGen's higher possible upside, analysts clearly believe FibroGen is more favorable than Coherus Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is FGEN or CHRS more profitable? FibroGen has a net margin of -9.73% compared to Coherus Oncology's net margin of -66.30%. Company Net Margins Return on Equity Return on Assets FibroGen-9.73% N/A -24.77% Coherus Oncology -66.30%N/A -26.51% Which has higher earnings and valuation, FGEN or CHRS? Coherus Oncology has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$29.62M0.98-$47.58M-$2.50-2.86Coherus Oncology$266.96M0.38$28.51M-$1.13-0.78 SummaryCoherus Oncology beats FibroGen on 10 of the 15 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.90M$2.42B$5.55B$9.09BDividend YieldN/A1.81%5.07%4.03%P/E Ratio-2.869.2228.2520.31Price / Sales0.98727.94433.2199.68Price / CashN/A22.3426.2427.98Price / Book-0.144.638.125.50Net Income-$47.58M$30.99M$3.19B$250.38M7 Day Performance25.66%4.80%3.62%4.79%1 Month Performance8.37%8.17%5.98%9.59%1 Year Performance-72.50%-3.88%29.39%16.41% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.7195 of 5 stars$7.15-2.7%$250.00+3,396.5%-72.5%$28.90M$29.62M-2.86570Positive NewsCHRSCoherus Oncology3.7926 of 5 stars$0.75-7.9%$4.68+527.6%-47.0%$86.51M$266.96M-0.66330News CoverageMGNXMacroGenics4.2533 of 5 stars$1.36-6.8%$5.71+320.2%-65.7%$85.80M$149.96M-1.53430News CoverageAnalyst UpgradeZNTLZentalis Pharmaceuticals2.2166 of 5 stars$1.19-5.6%$8.37+603.1%-66.5%$85.62M$26.87M-0.38160News CoverageELUTElutia3.4412 of 5 stars$2.08-0.5%$8.00+284.6%-45.7%$85.53M$24.38M-1.08180Gap UpTCRXTScan Therapeutics3.6057 of 5 stars$1.45-4.0%$7.80+437.9%-73.1%$85.45M$4.42M-1.33100News CoverageAnalyst UpgradeEXOZeXoZymesN/A$10.18+2.7%N/AN/A$85.21M$70K0.0029Positive NewsGap DownCLYMClimb Bio3.511 of 5 stars$1.26-1.6%$9.00+614.3%N/A$85.15MN/A-0.539News CoveragePositive NewsCYCCCyclacel Pharmaceuticals1.3363 of 5 stars$3.57+0.8%N/A-99.1%$84.82M$40K-0.0614Analyst UpgradeStock SplitGap UpHigh Trading VolumeIVVDInvivyd3.4652 of 5 stars$0.70-4.3%$5.85+731.4%-37.9%$84.40M$25.38M-0.59100FBRXForte Biosciences3.5262 of 5 stars$12.65-7.4%$61.00+382.2%+48,223.6%$83.24MN/A-0.785Options VolumeGap Down Related Companies and Tools Related Companies Coherus Oncology Competitors MacroGenics Competitors Zentalis Pharmaceuticals Competitors Elutia Competitors TScan Therapeutics Competitors eXoZymes Competitors Climb Bio Competitors Cyclacel Pharmaceuticals Competitors Invivyd Competitors Forte Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
